ARCHIVES

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

This article is from The Cancer Letter archive.

Vol. 26 No. 5 | May 30, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Amends FCRF RFP, Extends Deadline To Nov. 10

August 22, 1986

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

Group Chairs Seek Role Running NCTN

September 12, 2014

Brain tumor foundations form collaboration.

July 15, 2005

Committee Approves NDA For Tamoxifen

January 21, 1977

NCI Programs: Unequal Outcomes For Minorities The Result of Unequal Treatment NCI Suggests Awareness Campaign

December 17, 1999